Kyrollis Attalla has identified TIM-3 and TIGIT as promising targets for monotherapy or combination therapy with other immune checkpoint inhibitors in patients with urothelial cancer of the bladder. The gene discussed is HAVCR2; the disease is bladder transitional cell carcinoma.